Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Frank Ziemer Holding AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, PURDY, KYLE A, and is categorized within a distinct art unit. PURDY, KYLE A is the busiest examiner for the portfolio, overseeing 1 pending office action.
The single pending office action and distinct art unit indicate a very specific and limited prosecution presence at this time. Because there is only 1 pending office action, PURDY, KYLE A is the sole examiner interacting with the company's biotechnology and pharmaceutical filings. This centralized structure means that the company's current success in this technology area depends on the review of this one individual. This focus allows the company to direct its attention toward a single critical patent matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611811 | EYE COLORANT AND METHOD FOR MANUFACTURING A PATIENT INDIVIDUAL EYE COLORANT | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18611811 | EYE COLORANT AND METHOD FOR MANUFACTURING A PATIENT INDIVIDUAL EYE COLORANT | PURDY, KYLE A | 1611 | §102 | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFrank Ziemer Holding AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyle A Purdy has the most, with 1 of Frank Ziemer Holding AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.